Sight Sciences closes $30 million funding round

Sight Sciences has closed a $30 million Series E preferred stock financing round, the company announced in a press release.

Led by D1 Capital Partners, the proceeds of the round will be used to support commercial expansion of the Omni and TearCare products, the release said.

“We are extremely excited to partner with D1 over the long term,” Paul Badawi, founder and CEO of Sight Sciences, said in the release. “This investment further validates the substantial progress we have made in our mission to transform the treatment of the world’s most prevalent eye diseases. Through further clinical trials and continued scale-up of our commercial infrastructure, we are looking forward to accelerating the market development of both stand-alone MIGS with Omni and procedure-based dry eye therapy with TearCare.”

Sight Sciences has closed a $30 million Series E preferred stock financing round, the company announced in a press release.

Led by D1 Capital Partners, the proceeds of the round will be used to support commercial expansion of the Omni and TearCare products, the release said.

“We are extremely excited to partner with D1 over the long term,” Paul Badawi, founder and CEO of Sight Sciences, said in the release. “This investment further validates the substantial progress we have made in our mission to transform the treatment of the world’s most prevalent eye diseases. Through further clinical trials and continued scale-up of our commercial infrastructure, we are looking forward to accelerating the market development of both stand-alone MIGS with Omni and procedure-based dry eye therapy with TearCare.”